List of Excipients in Branded Drug OXISTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
PharmaDerm a division of Fougera Pharmaceuticals Inc	OXISTAT	oxiconazole nitrate	10337-358	BENZOIC ACID
PharmaDerm a division of Fougera Pharmaceuticals Inc	OXISTAT	oxiconazole nitrate	10337-358	CETYL ALCOHOL
PharmaDerm a division of Fougera Pharmaceuticals Inc	OXISTAT	oxiconazole nitrate	10337-358	PETROLATUM
PharmaDerm a division of Fougera Pharmaceuticals Inc	OXISTAT	oxiconazole nitrate	10337-358	POLYSORBATE 60
PharmaDerm a division of Fougera Pharmaceuticals Inc	OXISTAT	oxiconazole nitrate	10337-358	PROPYLENE GLYCOL

Oxistat Excipient Strategy and Commercial Opportunities for Oxiconazole Nitrate

Last updated: August 4, 2026

Oxistat is a topical oxiconazole nitrate product available as a 1% cream and lotion for dermatophyte and yeast skin infections. Its molecule is mature, generic competition is established, and conventional composition patents are unlikely to provide durable exclusivity. The strongest commercial opportunity is a differentiated topical platform built around skin feel, adherence, packaging, preservative tolerance, and a streamlined FDA abbreviated new drug application (ANDA) strategy.

What is Oxistat and how is it used?

Oxistat contains oxiconazole nitrate, a topical imidazole antifungal. U.S. labeling identifies cream and lotion dosage forms for treatment of tinea pedis, tinea cruris, and tinea corporis caused by susceptible organisms. The product is prescription-only in the United States.[1]

Attribute	Oxistat profile
Active ingredient	Oxiconazole nitrate
Strength	1%
Dosage forms	Cream and lotion
Therapeutic class	Topical imidazole antifungal
FDA pathway	Originally approved NDA; generic products generally use the ANDA pathway
Main indications	Tinea pedis, tinea cruris, tinea corporis
Product type	Small-molecule topical drug
Biosimilar exposure	Not applicable
Primary commercial issue	Differentiation in a mature generic market

Oxiconazole inhibits fungal lanosterol 14-alpha-demethylase, reducing ergosterol synthesis and disrupting fungal cell membranes. The clinical value proposition is broad topical antifungal activity combined with once-daily administration in labeled use.

What excipients are used in Oxistat cream and lotion?

The FDA product labeling identifies materially different excipient systems for the cream and lotion.[1]

Oxistat cream excipients

The labeled inactive ingredients include:

• Benzyl alcohol
• Cetyl alcohol
• Mineral oil
• Polysorbate 60
• Purified water
• Sodium hydroxide
• Stearyl alcohol

This is a conventional oil-in-water emulsion. Cetyl alcohol and stearyl alcohol provide viscosity, emulsion structure, and emollience. Mineral oil supplies the oil phase and contributes to occlusion. Polysorbate 60 supports emulsification. Benzyl alcohol functions primarily as a preservative and may also contribute to fragrance and sensory characteristics. Sodium hydroxide adjusts pH.

Oxistat lotion excipients

The labeled lotion system includes:

• Carbomer 934P
• Cetyl alcohol
• Polysorbate 60
• Propylene glycol
• Purified water
• Sodium hydroxide

The lotion uses a polymer-thickened aqueous system rather than the more occlusive mineral-oil cream base. Carbomer 934P provides rheology and suspension stability. Propylene glycol functions as a humectant, solvent, and penetration-supporting vehicle. Sodium hydroxide neutralizes the carbomer and controls viscosity and pH.

The two dosage forms create a basic product-segmentation strategy: cream for more emollient and occlusive application, lotion for spreadability and lighter sensory performance.

How should an excipient strategy be designed for an Oxistat generic?

A generic Oxistat developer should prioritize pharmaceutical equivalence, topical product performance, tolerability, manufacturing robustness, and user acceptability.

1. Preserve the established cream architecture

A direct cream generic should initially use an excipient system close to the reference product. The original architecture has several advantages:

• Familiar sensory profile
• Low formulation development risk
• Established manufacturing process
• Easier justification of physicochemical comparability
• Lower risk of unexpected irritation
• Straightforward scale-up using standard emulsion equipment

The main development risk is batch-to-batch control of droplet size, viscosity, pH, active distribution, and water activity. These variables can affect drug release and topical bioequivalence.

2. Develop a low-irritation alternative

Benzyl alcohol and propylene glycol can cause irritation or sensitization in some users. A differentiated product could evaluate:

• Phenoxyethanol-based preservation
• Benzoate or sorbate systems, where pH permits
• Reduced preservative concentration
• Preservative-free packaging for selected presentations
• Alternative glycols or humectants
• Lower-irritancy emollients in place of part of the mineral-oil phase

Any change must be evaluated against antimicrobial effectiveness, active stability, packaging compatibility, skin irritation, sensitization, and FDA inactive ingredient precedents.

A preservative-free version may have commercial value, but it creates packaging and microbiological-control costs. Airless pumps, unit-dose sachets, or sealed metered dispensers may be necessary. The opportunity is strongest in patients with sensitive or compromised skin, but the product must maintain competitive cost.

3. Optimize sensory performance

Topical antifungals compete partly on adherence. A cream that feels greasy, remains wet, pills under clothing, or leaves visible residue may reduce use even when pharmacologically effective.

Formulation targets should include:

• Rapid rub-in
• Low tack
• Limited whitening
• Reduced residue on socks and clothing
• Controlled occlusion
• Stable viscosity across temperature ranges
• Good spreadability over the feet and groin
• Minimal fragrance or odor

A light cream or lotion can be commercially differentiated without changing the active ingredient. The developer should, however, expect a higher regulatory burden if the composition departs materially from the reference product.

4. Improve delivery to thick or difficult-to-treat skin

Tinea pedis often involves the interdigital spaces and plantar skin. The formulation must distribute across irregular surfaces and remain in place during activity.

Potential approaches include:

• Controlled use of propylene glycol or another solvent
• Emulsion systems with optimized skin partitioning
• Film-forming polymers
• Low-level occlusive excipients
• Rheology that supports vertical retention without excessive tack
• Sprayable or foam-like delivery for hard-to-reach areas

Film-forming systems could support once-daily adherence, but they may create a new product rather than a simple generic equivalent. A film former may also alter drug release, residual drug levels, wash-off behavior, and local tolerability.

What formulation patents could protect an Oxistat follow-on product?

The oxiconazole molecule and conventional Oxistat composition are mature technologies. New patent value would more likely arise from a specific formulation, delivery system, manufacturing process, or use limitation.

Potential patentable areas

Innovation area	Possible claim focus	Commercial value
Low-irritation formulation	Preservative-free or reduced-sensitizer composition	Moderate
Film-forming product	Defined polymer and solvent system	Moderate to high
Foam or spray	Aerosol or pump delivery with defined deposition	Moderate
Enhanced penetration	Specific excipient ratio and skin-delivery profile	Moderate
Controlled release	Sustained topical release matrix	High if clinically meaningful
Packaging	Metered-dose, airless, or unit-dose delivery	Low to moderate
Manufacturing	Defined mixing, homogenization, or particle-size process	Moderate
Combination product	Oxiconazole with another active ingredient	High, but requires new clinical and regulatory support

Patent claims based only on routine excipient substitution are vulnerable to obviousness challenges. Stronger claims would connect composition to a measurable technical result, such as improved in vitro release, reduced irritation, increased residence time, improved stability, or a clinically relevant dosing advantage.

A formulation patent should include broad genus claims, narrower species claims, excipient-ratio claims, process claims, and packaging claims. The patent term clock begins at filing, so the developer must balance early filing against the need for robust comparative data.

When does Oxistat lose exclusivity?

Oxistat is an established small-molecule product, and its original regulatory and patent exclusivity periods have expired. The principal U.S. entry route is therefore generic competition through ANDAs rather than biosimilar litigation or a new chemical entity exclusivity framework.

FDA exclusivity status

Exclusivity category	Oxistat relevance
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the approved product
Pediatric exclusivity	No current commercial significance
Biologic exclusivity	Not applicable
180-day generic exclusivity	Depends on a specific first-filer and Orange Book status
Patent-based exclusivity	Must be assessed against current Orange Book listings

The Orange Book should be reviewed for current patents, paragraph IV certifications, and any active exclusivity codes associated with the relevant oxiconazole nitrate reference product.[2] For a mature product, the commercial question is less whether the original product remains protected and more whether a new generic can achieve an acceptable cost structure and obtain approval without a formulation-related delay.

Are there Paragraph IV challenges to Oxistat?

Paragraph IV litigation risk is generally limited for an old topical drug unless an active Orange Book-listed patent remains relevant or a sponsor lists a later formulation patent.

An ANDA applicant may certify that a listed patent is invalid, unenforceable, or will not be infringed. That certification can trigger litigation under the Hatch-Waxman framework. For Oxistat, the likely risk profile is:

1. Low risk from expired original patents.
2. Potential risk from any later-listed formulation, method-of-use, or delivery patent.
3. Greater risk if the applicant seeks approval for a differentiated dosage form with a separate patent estate.
4. Lower risk where the ANDA uses a conventional composition and makes a paragraph III certification to wait for patent expiry.

A paragraph IV strategy can accelerate market positioning but may require substantial litigation expense. For a low-priced topical antifungal, the expected value of litigation depends heavily on anticipated market share and the number of competing ANDA applicants.

What is the FDA regulatory status of Oxistat generics?

A conventional oxiconazole nitrate cream or lotion is generally positioned through the ANDA route if the applicant can demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.

Topical semisolid products require more than simple chemical sameness. FDA assessment may include:

• Qualitative and quantitative composition
• Active ingredient identity and strength
• Dosage-form similarity
• Particle size and morphology
• Globule or droplet size for emulsions
• pH
• Viscosity and rheology
• Specific gravity
• Water activity
• Microbial limits
• Preservative effectiveness
• In vitro release testing
• In vitro permeation testing where relevant
• Comparative characterization against the reference product

FDA guidance on topical dermatological products emphasizes formulation sameness, product performance, and comparative quality attributes.[3] A composition that is clinically acceptable but materially different from the reference can increase the need for additional studies.

What commercial opportunities exist for Oxistat excipients?

The best opportunities fall into four segments.

Low-cost generic cream

This is the most direct opportunity. The product would use an excipient system close to the reference cream and compete on:

• Manufacturing cost
• Supply reliability
• Retail and pharmacy contracts
• Tube size
• Reimbursement access
• Avoidance of back orders

The market is likely price-sensitive, so a low-cost, robust formulation has greater value than an expensive delivery innovation unless the innovation supports premium reimbursement.

Low-irritation product

A benzyl-alcohol-reduced or preservative-free product could target patients who discontinue topical therapy because of stinging, dryness, or irritation. The main commercial advantages would be patient experience and specialty-pharmacy positioning.

Lotion and high-spreadability formats

Lotion may be preferred for larger affected areas or hairy skin. A manufacturer could develop a better-spreading lotion with low residue and controlled viscosity. This segment may support differentiated packaging and direct-to-consumer positioning if the regulatory status and labeling permit.

Novel delivery formats

Foam, spray, film-forming, and metered-dose formats could improve convenience. These products would require more development work and may no longer qualify as simple substitutes for the reference cream or lotion. Their value depends on a clinically or commercially meaningful adherence advantage.

How strong is the Oxistat patent estate?

The legacy patent estate is weak as a source of new exclusivity because oxiconazole nitrate is an old small-molecule antifungal and the original product has long been commercialized. A new sponsor could still create a moderate-strength estate around a differentiated formulation.

Patent layer	Expected strength
Oxiconazole composition-of-matter patents	Expired or commercially irrelevant
Conventional cream composition	Low
Conventional lotion composition	Low
Novel excipient ratios tied to performance	Moderate
Preservative-free packaging system	Moderate
Film-forming or controlled-release platform	Moderate to high
New combination therapy	Potentially high, with greater regulatory burden
Manufacturing process claims	Moderate, but difficult to enforce commercially
Method-of-use claims	Variable and dependent on approved labeling

The strongest defensible position would combine formulation claims with process, packaging, and method-of-use claims. A single narrow composition claim would be easier for competitors to design around.

What manufacturing and IP barriers affect Oxistat competition?

Manufacturing barriers are manageable but not trivial. The main technical risks are emulsion instability, active uniformity, viscosity drift, preservative failure, and scale-up differences.

Key manufacturing controls

• Controlled heating and cooling of oil and aqueous phases
• Homogenization profile
• Oxiconazole particle-size control
• Order of excipient addition
• Neutralization endpoint for carbomer systems
• Air incorporation
• Filling temperature
• Tube and pump compatibility
• Long-term and accelerated stability
• Microbial control

Packaging can materially affect product quality. Aluminum tubes may provide strong barrier properties but can interact with formulation components if internal coatings are inadequate. Laminated tubes and airless pumps offer different cost, barrier, and dispensing profiles.

Geographic commercial opportunities exist in the United States, Europe, Canada, Latin America, and selected Asian markets, but regulatory requirements differ. The U.S. market emphasizes ANDA comparability and Orange Book strategy. Europe may require a generic or hybrid application under national or centralized procedures, with different expectations for topical equivalence. Emerging markets may be more accessible but are more exposed to price erosion and local manufacturing requirements.

Which companies are positioned to compete with Oxistat?

Competition can come from several groups:

• Generic dermatology manufacturers
• Contract development and manufacturing organizations
• Established topical pharmaceutical companies
• Specialty-generic companies
• Consumer-health companies seeking an OTC antifungal platform
• Regional manufacturers with low-cost semisolid capacity

The most credible competitors are companies with existing topical manufacturing, dermatology sales channels, and access to oxiconazole nitrate API. API supply is not expected to be the main barrier. The harder commercial requirements are formulation reproducibility, FDA approval, reimbursement access, and retail distribution.

What revenue exposure does Oxistat create?

Oxistat revenue exposure is likely limited at the molecule level because oxiconazole is a mature generic antifungal. A sponsor should not assume that a new formulation will command a premium merely because it has a novel excipient system.

Commercial upside depends on:

• Number of active generic competitors
• Wholesale acquisition price
• Payer reimbursement
• Product availability
• Tube and lotion size
• Pharmacy substitution
• Prescriber awareness
• Consumer adherence
• Ability to obtain formulation-based protection
• Whether the product remains prescription-only or qualifies for a separate regulatory strategy

A conventional generic is a volume and cost-control play. A differentiated formulation is a brand-building play with higher development risk and potentially stronger margins.

Key Takeaways

• Oxistat is a 1% oxiconazole nitrate topical cream and lotion.
• Its labeled excipients are conventional: the cream uses mineral oil, fatty alcohols, polysorbate 60, and benzyl alcohol; the lotion uses carbomer, propylene glycol, cetyl alcohol, and polysorbate 60.[1]
• Original molecule and regulatory exclusivity are no longer the main barriers to entry.
• The most practical generic strategy is close compositional alignment with the reference product.
• The most attractive innovation areas are low-irritation preservation, improved sensory properties, film-forming delivery, metered packaging, and better adherence.
• New patents must tie excipient selection to measurable performance or clinical advantages.
• Biosimilar competition does not apply because oxiconazole is a small molecule.
• The commercial opportunity is strongest for manufacturers with topical semisolid capacity, reliable API sourcing, and established dermatology distribution.
• Conventional generic competition is likely to produce price pressure; differentiated formulations offer greater margin potential but require more regulatory and clinical support.

FAQs

Can oxiconazole nitrate be formulated as a preservative-free cream?

Yes. A preservative-free formulation is technically feasible, but it would require validated microbiological controls, suitable packaging, stability data, and evidence that the formulation remains equivalent in performance to the reference product.

Is propylene glycol essential in an oxiconazole lotion?

No. Propylene glycol is a multifunctional excipient, but alternative solvents or humectants may be evaluated. Replacing it can change viscosity, drug release, skin penetration, irritation, and preservative performance.

Can a new oxiconazole foam receive separate patent protection?

Potentially. A foam could support composition, propellant, packaging, and use claims if the formulation has defined technical advantages. The claims would need to distinguish the product from predictable topical antifungal formulations.

Does an Oxistat formulation change automatically require clinical trials?

No. The required evidence depends on the extent of the change and the regulatory pathway. A composition close to the reference product may rely on comparative pharmaceutical and performance testing, while a materially different delivery system may require additional clinical or pharmacokinetic evidence.

Could Oxistat become an over-the-counter antifungal product?

A separate OTC strategy would require FDA review of the active ingredient, indication, labeling, dosage form, and applicable OTC monograph or nonmonograph pathway. Existing prescription approval does not automatically authorize OTC marketing.

References

1. U.S. Food and Drug Administration. (n.d.). Oxistat (oxiconazole nitrate) cream and lotion, 1%: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (2022). Acyclovir cream; acyclovir ointment; and other topical dermatological drug products: Development and submission of abbreviated new drug applications. FDA guidance for industry.

4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.